You just read:

ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program

News provided by

ImmunoCellular Therapeutics, Ltd.

Mar 06, 2017, 06:00 ET